SenzaGen announced that the company has recruited Anna Chérouvrier Hansson as chief commercial officer and Dr. Henrik Appelgren as chief scientific officer. The company's management is thus strengthened in the run-up to the commercialization of the company's GARD tests, which are used to assess the allergenic properties of chemical substances. The appointments announced are the final stage in the work to strengthen company's management for the commercialization of the GARD tests and the company's planned listing on Nasdaq First North. The management team has been built up gradually over the past year - at the end of 2016 Marianne Olsson started work as Chief Financial Officer, and in early 2017 Dr. Steve Smith was recruited to the post of Intellectual Property Counsel. Anna Chérouvrier Hansson comes most recently from a position as Director of Marketing at Camurus. There she was responsible for the company's marketing department, the development and management of the medical device marketing and sales organisation and for the establishment of distribution partnerships in Asia, the USA and France. She has previously worked as Head of Business Development Life Science at Invest in Skåne, Partner at Zitha Consulting and in a number of senior positions in European pharmaceutical and chemical companies. Henrik Appelgren is a biologist with a PhD in genetic toxicology. He has been working at the Swedish Chemicals Agency for 15 years, where he worked as Sweden's national coordinator in the OECD Test Guideline Programme. Henrik has a deep knowledge in alternative test methods and of regulatory work in the chemical industry - both nationally and internationally. He also has long experience of health risk assessments of chemicals in all European legislation. He is, or has been, a member of several scientific expert councils including FORMAS, the Swedish Research Council, the Swedish Fund for Research Without Animal Experiments, the Scandinavian Society for Cell Toxicology and EUToxRisk. Anna Chérouvrier Hansson takes up her position on August 15, 2017 and Henrik Appelgren on September 4, 2017.